Tag: Abbott

Abbott starts trial to evaluate TriClip for percutaneous repair of tricuspid...

Abbott has announced its TRILUMINATE pivotal trial to evaluate the safety and effectiveness of the TriClip transcatheter tricuspid valve repair system for the treatment...

ESC 2019: Two-year findings of MITRA-FR continue to show no prognosis...

At the European Society of Cardiology Congress (ESC 2019; 31 August–4 September, Paris, France), Jean-Francois Obadia (Hopital Cardiovasculaire Louis Pradel, Chirurgie Cardio-Vasculaire et Transplantation...

Fourth-generation MitraClip receives FDA approval

According to a statement, Abbott has announced it has received US Food and Drug Administration (FDA) approval for the fourth-generation MitraClip heart valve repair...

MitraClip can be used to treat secondary mitral regurgitation in the...

The US FDA has approved a new indication for percutaneous edge-to-edge repair (MitraClip, Abbott), allowing its use for the reduction of moderate-to-severe or severe...

CRT 2019: US FDA approves resting full-cycle ratio for measuring severity...

Abbott has announced the US FDA clearance of the resting full-cycle ratio (RFR) diagnostic test to identify significant narrowing of arteries in patients with...

Abbott to acquire Cephea Valve Technologies

It was recently announced that Abbott has exercised its option to purchase Cephea Valve Technologies. Financial terms were not disclosed. Abbott provided capital and...

FDA approves world’s first device for treatment of premature babies and...

The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the world's first medical device that can be implanted in...

US FDA approve HeartMate 3 heart pump for advanced heart failure...

The HeartMate 3 left ventricular assist device has received US FDA approval as a destination therapy for people living with advanced heart failure. With...

TCT 2018: One-year real-world results show Portico TAVI system reduces severe...

According to one-year results from the PORTICO I study, which were presented during a late-breaking session at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting...

ESC 2018: MitraClip makes “absolutely no difference” for the prognosis...

The first randomised controlled trial to compare percutaneous edge-to-edge repair (MitraClip, Abbott) with medical therapy alone in patients with secondary mitral regurgitation (to heart...

Abbott launches trial of its Tendyne transcatheter mitral valve implantation device

Abbott has initiated a pivotal clinical study in the USA of its Tendyne transcatheter mitral valve implantation (TMVI) system for the treatment of mitral...

Next-generation of MitraClip approved for use in the USA

Abbott has received approval from the US FDA for a next-generation version of its MitraClip heart valve repair device used to reduce mitral regurgitation....

Xience Sierra approved for use in USA

Abbott has announced it has received approval from the US FDA for its Xience Sierra, the newest generation of the company’s gold-standard Xience everolimus-eluting...

FDA approves the world’s smallest mechanical heart valve

The US FDA has approved the Masters HP 15mm rotatable mechanical heart valve (Abbott), which a press release says is the world’s smallest mechanical...

First patient enrolled in trial reviewing 28-day DAPT with Xience

The first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet therapy (DAPT) in patients at high risk of...

TCT 2017: Advances in device technology needed to improve outcomes with...

Data from the ABSORB IV study indicate that device thrombosis with the bioresorbable vascular scaffold (Absorb, Abbott) is substantially reduced when the device is...

MitraClip becomes first approved device for transcatheter mitral valve repair in...

Abbott has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved its MitraClip device for treatment of people with mitral regurgitation....

Abbott’s Full MagLev HeartMate 3 LVAD receives FDA approval

The FDA has approved the Full MagLev HeartMate 3 (Abbott) left ventricular assist device for use in heart failure patients in need of short-term...

US trial to evaluate safety and efficacy of Amplatzer for patent...

Abbott has initiated a US pivotal clinical study evaluating the safety and effectiveness of a modified version of its Amplatzer device to correct patent...

Millipede 50mm annuloplasty ring used in first cases

Millipede has announced the successful implantation of its newest 50mm Iris annuloplasty ring, with a transfemoral, transseptal delivery catheter, in a functional mitral regurgitation...

ACC 2017: CardioMEMS HF system effective in reducing heart failure hospitalisations...

Late-breaking clinical research presented at the American College of Cardiology 66th Annual Scientific Sessions (ACC; 17-19 March, Washington, DC, USA) has shown treatment with...

Terumo signs to acquire St Jude Medical and Abbott’s vascular closure...

Terumo has reached an agreement with Abbott and St Jude Medical to acquire certain products owned by both for a total of US$1.12 billion. Based...

St. Jude Medical and Abbott to sell portion of vascular closure...

Abbott and St. Jude Medical have announced an agreement in principle to sell certain products to Terumo Corporation. The transaction reflects a purchase price of...